These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

324 related items for PubMed ID: 21900356

  • 1. Early onset of natalizumab-related progressive multifocal leukoencephalopathy.
    Damasceno A, von Glehn F, Martinez AR, Longhini AL, Deus-Silva L, Brandão CO, Santos LM, Damasceno BP.
    Mult Scler; 2011 Nov; 17(11):1397-8. PubMed ID: 21900356
    [No Abstract] [Full Text] [Related]

  • 2. Deaths and disability from natalizumab are no longer tolerable: Yes.
    Duquette P.
    Mult Scler; 2012 Aug; 18(8):1068-9. PubMed ID: 22807470
    [No Abstract] [Full Text] [Related]

  • 3. Deaths and disability from natalizumab are no longer tolerable: No - (they can be avoided).
    Sørensen PS.
    Mult Scler; 2012 Aug; 18(8):1070-2. PubMed ID: 22807471
    [No Abstract] [Full Text] [Related]

  • 4. Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped.
    Rispens T, Vennegoor A, Wolbink GJ, Polman CH, Killestein J.
    Mult Scler; 2012 Jun; 18(6):899-901. PubMed ID: 22183929
    [Abstract] [Full Text] [Related]

  • 5. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.
    N Engl J Med; 2012 May 17; 366(20):1870-80. PubMed ID: 22591293
    [Abstract] [Full Text] [Related]

  • 6. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
    Maillart E, Louapre C, Lubetzki C, Papeix C.
    Mult Scler; 2014 Apr 17; 20(4):505-9. PubMed ID: 24367037
    [Abstract] [Full Text] [Related]

  • 7. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
    Soilu-Hänninen M, Päivärinta M, Sonninen P, Parkkola R, Vuorinen T, Erälinna JP.
    Duodecim; 2013 Apr 17; 129(7):765-70. PubMed ID: 23720945
    [Abstract] [Full Text] [Related]

  • 8. The effect of plasma exchange on serum anti-JC virus antibodies.
    Subramanyam M, Plavina T, Khatri BO, Fox RJ, Goelz SE.
    Mult Scler; 2013 Jun 17; 19(7):912-9. PubMed ID: 23232602
    [Abstract] [Full Text] [Related]

  • 9. Transient punctuate enhancing lesions preceding natalizumab-associated progressive multifocal leukoencephalopathy.
    Taieb G, Renard D, Thouvenot E, Servillo G, Castelnovo G.
    J Neurol Sci; 2014 Nov 15; 346(1-2):364-5. PubMed ID: 25241939
    [No Abstract] [Full Text] [Related]

  • 10. Deaths and disability from natalizumab are no longer tolerable: Commentary.
    Hutchinson M.
    Mult Scler; 2012 Aug 15; 18(8):1073. PubMed ID: 22807472
    [No Abstract] [Full Text] [Related]

  • 11. Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.
    Vennegoor A, Rispens T, Van Oosten BW, Wattjes MP, Wondergem MJ, Teunissen CE, Van der Kleij D, Uitdehaag BM, Polman CH, Killestein J.
    Mult Scler; 2015 Apr 15; 21(4):481-4. PubMed ID: 25078275
    [Abstract] [Full Text] [Related]

  • 12. Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision.
    Tur C, Tintoré M, Vidal-Jordana A, Castilló J, Galán I, Río J, Arrambide G, Comabella M, Arévalo MJ, Horno R, Vicente MJ, Caminero A, Nos C, Sastre-Garriga J, Montalban X.
    Mult Scler; 2012 Aug 15; 18(8):1193-6. PubMed ID: 22383232
    [Abstract] [Full Text] [Related]

  • 13. JCV-negative natalizumab-associated progressive multifocal leukoencephalopathy: a clinico-radiological diagnosis.
    Travasarou M, Marousi S, Papageorgiou E, Karageorgiou CE.
    Clin Neurol Neurosurg; 2013 Jun 15; 115(6):827-9. PubMed ID: 22920632
    [No Abstract] [Full Text] [Related]

  • 14. Rituximab in relapsing-remitting multiple sclerosis.
    Schrijver HM.
    N Engl J Med; 2008 Jun 12; 358(24):2645; author reply 2646-7. PubMed ID: 18557177
    [No Abstract] [Full Text] [Related]

  • 15. Fingolimod treatment after natalizumab-related progressive multifocal leukoencephalopathy: three new cases.
    Peaureaux D, Pignolet B, Biotti D, Bucciarelli F, Gaina J, Bucur C, Clanet M, Martin-Blondel G, Brassat D.
    Mult Scler; 2015 Apr 12; 21(5):671-2. PubMed ID: 25305251
    [No Abstract] [Full Text] [Related]

  • 16. Predicting risk of progressive multifocal leukoencephalopathy from natalizumab.
    Ropper AH.
    N Engl J Med; 2012 May 17; 366(20):1938-9. PubMed ID: 22591300
    [No Abstract] [Full Text] [Related]

  • 17. Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy.
    Décard BF, Haghikia A, Tönnes C, Thöne J, Lukas C, Chan A, Gold R.
    Mult Scler; 2013 Feb 17; 19(2):249-51. PubMed ID: 22596228
    [Abstract] [Full Text] [Related]

  • 18. Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis.
    Schröder A, Lee DH, Hellwig K, Lukas C, Linker RA, Gold R.
    Arch Neurol; 2010 Nov 17; 67(11):1391-4. PubMed ID: 20625069
    [Abstract] [Full Text] [Related]

  • 19. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
    Bartt RE.
    Curr Opin Neurol; 2006 Aug 17; 19(4):341-9. PubMed ID: 16914971
    [Abstract] [Full Text] [Related]

  • 20. CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus.
    Warnke C, Smolianov V, Dehmel T, Andrée M, Hengel H, Zohren F, Arendt G, Wiendl H, Haas R, Hartung HP, Adams O, Kieseier BC.
    Mult Scler; 2011 Feb 17; 17(2):151-6. PubMed ID: 21078695
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.